March 17, 2022
National Center of Neurology and Psychiatry
Study shows the efficacy of antisense oligonucleotide-based exon 44 skipping drug, NS-089/NCNP-02, for patients with Duchenne muscular dystrophy (DMD)

March 15, 2022
PepGen Announces Approval by Health Canada of CTA to Begin First in Human Trials of PGN-EDO51 to Treat Duchenne Muscular Dystrophy

February 22, 2022
Code Biotherapeutics
Code Biotherapeutics Announces Collaboration with Takeda to Use Proprietary 3DNA Genetic Medicine Delivery Platform to Design and Develop Gene Therapies for Rare Diseases

January 13, 2022
Solid Biosciences
Letter to the Duchenne Community: IGNITE DMD Phase I/II Clinical Trial and 2022 Priorities

September 27, 2021
Sarepta Therapeutics
Sarepta Therapeutics to Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive Interactions with FDA

January 07, 2021
Pfizer Doses First Participant in Phase 3 Study for Duchenne Muscular Dystrophy Investigational Gene Therapy

January 05, 2021
PR Newswire
REGENXBIO Announces Update on RGX-314 and Pivotal Program for the Treatment of Wet AMD and New Gene Therapy Program for the Treatment of Duchenne Muscular Dystrophy

December 09, 2020
Globe Newswire
PepGen therapy targeting skeletal and cardiac muscle

December 07, 2020
Globe Newswire
Sarepta Therapeutics Announces Positive Clinical Results from MOMENTUM, a Phase 2 Clinical Trial of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51

Hike for Hope is operating under the HIKE FOR HOPE FOUNDATION INC
936 W Francis St., Aspen, CO. 81611
Tel: 970-925-6137,
Tax-exempt 501 (c)(3)
charitable organization.
Tax ID 20-3596738